e-learning
resources
Glasgow 2004
Monday 06.09.2004
Heart and lung
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease
M. C. Ronchi, A. Fabbri, F. Vannucci, A. Sanna, M. Grazzini, M. Guerrini, R. Culli, P. Apicella, F. Innocenti (Pistoia, Italy)
Source:
Annual Congress 2004 - Heart and lung
Session:
Heart and lung
Session type:
Thematic Poster Session
Number:
1822
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. C. Ronchi, A. Fabbri, F. Vannucci, A. Sanna, M. Grazzini, M. Guerrini, R. Culli, P. Apicella, F. Innocenti (Pistoia, Italy). Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease. Eur Respir J 2004; 24: Suppl. 48, 1822
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The impact of anti-IgE treatment on the airway microbiome in asthma.
Chest X-ray and CT
Bronchoalveolar lavage (techniques, indications, results)
Related content which might interest you:
Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids
Source: Eur Respir J 2001; 17: 337-342
Year: 2001
Effect of statin therapy in patients with lung cancer on mortality, incidence of infections and pulmonary embolism
Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer
Year: 2012
Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease
Source: Annual Congress 2004 - Treatment of pulmonary hypertension
Year: 2004
The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2007; 30: Suppl. 51, 357s
Year: 2007
Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
A comparison of the effects of lung function between low dose theophylline and oral β2-agonist in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2006; 28: Suppl. 50, 215s
Year: 2006
Predictors of effects and adverse effects of pirfenidone on idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Does atorvastatin have effect on lung function and morbidity as add-on therapy in asthmatic patients?
Source: Annual Congress 2007 - New drugs for asthma
Year: 2007
Inhaled treprostinil therapy in patients with pulmonary hypertension and parenchymal lung disease
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
The effect of augmentation therapy on systemic and pulmonary inflammation markers in α1-antitrypsin deficiency patients
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
Compliance with nebulized therapy in patients with chronic lung disease
Source: Eur Respir J 2001; 18: Suppl. 33, 59s
Year: 2001
Pulmonary and systemic inflammatory response in patients with pulmonary infections receiving long-term glucocorticoid therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 15s
Year: 2002
Impact of inhaled corticosteroids in patients with cardiovascular disease
Source: Eur Respir Monogr 2020; 88: 251-263
Year: 2020
Sulphasalazine and lung toxicity
Source: Eur Respir J 2002; 19: 756-764
Year: 2002
Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension
Source: Eur Respir Rev 2015; 24: 272-282
Year: 2015
The effect of statin therapy in patients with chronic obstructive airway disease
Source: International Congress 2015 – COPD: notable points
Year: 2015
Intravenous iloprost as "rescue therapy" in patients with severe primary pulmonary hypertension deteriorating while on chronic aerosolized iloprost therapy
Source: Eur Respir J 2004; 24: Suppl. 48, 705s
Year: 2004
Effect of long-term specific therapy in a cohort of 33 patients with pulmonary arterial hypertension of various etiologies
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 514s
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept